SCHEMBL31023705

SCHEMBL31023705

CCOC(=O)N1CCCC(C(c2ccc3c(c2)COCO3)c2ccc3c(c2)COCO3)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 2/20 0.46
▸ ALDH1A1 P00352 4/20 0.42
▸ HPGD P15428 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ FAAH O00519 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ KDM4E B2RXH2 3/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CHRM2 P08172 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ APEX1 P27695 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ CTDSP1 Q9GZU7 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023708 0.96 MGLL (0.48) MGLLALDH1A1HPGDPOLBFAAH
SCHEMBL31023696 0.81 CHRM1 (0.38) MGLLFAAHMAPT
SCHEMBL31023894 0.76 MGLL (0.49) MGLLFAAH
SCHEMBL31023851 0.73 ALDH1A1 (0.41) MGLLALDH1A1HPGDPOLBMAPT
SCHEMBL31023793 0.72 MAPT (0.49) ALDH1A1POLBMAPTL3MBTL1MAPK1
SCHEMBL31023785 0.72 MGLL (0.51) MGLLFAAH
SCHEMBL31023665 0.72 ALDH1A1 (0.43) MGLLALDH1A1HPGDPOLBMAPT
SCHEMBL31023835 0.71 SLC6A2 (0.35) MGLLHPGDFAAHCHRM2
SCHEMBL31023655 0.70 MGLL (0.38) MGLLALDH1A1HPGDKDM4EKMT2A
SCHEMBL31023645 0.70 SLC6A2 (0.38) MGLLFAAHCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 — — EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 — — US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 — — US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL MGLL 1/4885ALDH1A1 530/4885HPGD 1304/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL MGLL 1/4885ALDH1A1 530/4885HPGD 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback